Answers are grounded in this paper and cite their sources.
Case series demonstrates successful treatment using peripheral centrifugal plasma exchange in IVIG-resistant Kawasaki disease, suggesting a less invasive alternative to membrane plasma exchange.
Centrifugal therapeutic plasma exchange (cTPE) enables plasma removal at lower blood flow rates and can be performed using peripheral vascular access (VA), potentially reducing the invasiveness of plasma exchange in pediatric patients. We report four cases of intravenous immunoglobulin (IVIG)-resistant Kawasaki disease (KD) successfully treated with cTPE between illness days 8 and 12. All procedures were performed using peripheral VA under local anesthesia and continuous sedation with propofol. All sessions were performed with red blood cell (RBC) priming. Five-percent albumin was used as the sole replacement fluid, and the exchange volume was set at 1.0–1.5 times the estimated plasma volume. All patients completed 2–4 sessions without major complications or need for intubation. One patient developed transient coronary dilatation that regressed, whereas the remaining 3 had no coronary artery lesions. The median blood flow rate and treatment duration were 2.3 (1.8–2.8) mL/kg/min and 93 (69–118) minutes, respectively, with median reduction rates of immunoglobulin G (IgG) and fibrinogen of 67.3% and 66.8%. No clinically significant hypocalcemia or thrombocytopenia occurred. These findings suggest that cTPE using peripheral VA can be safely and effectively performed in patients with IVIG-resistant KD, offering a less invasive and feasible alternative to membrane TPE, which has been the predominant modality in Japan.
No takes yet. Share an insight, caveat, or question.
Omori et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: